Cellectar CLRB 深 沪
等待开盘 05-11 09:30:00 美东时间
3.10
-0.200
-6.06%
华盛通- 最 高3.62
- 今 开3.21
- 成交量 65.39万股
- 最 低 2.91
- 昨 收 3.30
- 总市值 18.94万
- 52周最高 10.19
- 市盈率 静 --
- 换手率 1070.11%
- 52周最低 0.2402
- 委 比 92.18%
- 总股本 6.11万
- 历史最高 920.00
- 量 比 0.06
- 振 幅 21.52%
- 历史最低 0.224
- 每 手 1
- 风险率 1.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crude Oil Down 4%; PayPal Shares Fall After Q1 Results
US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.
05-06 01:13
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside $140 million financing.
05-05 21:50
Market-Moving news for May 5th
PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. CLRB: 145% | Cellectar Biosciences Phase
05-05 19:19
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of Bark Inc (NYSE:BARK) rose sharply in pre-market trading after a 13D f...
01-12 17:34
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Earnings Outlook For Cellectar Biosciences
Cellectar Biosciences (NASDAQ:CLRB) is set to give its latest quarterly earning...
2025-11-13 01:03
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
Cellectar Biosciences will implement a 1-for-30 reverse stock split on June 24, reducing its outstanding shares from 54.36 million to approximately 1.81 million.
2025-06-18 20:30
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
Cellectar Biosciences reported initial results from its CLOVER-2 trial, showing pediatric patients with relapsed/refractory high-grade glioma (pHGG) receiving iopofosine I 131 achieved an average of 5.4 months of PFS and 8.6 months of OS. The drug demonstrated manageable toxicities primarily affecting the hematologic system, with no significant cardiovascular, renal, or liver issues. The study continues to evaluate the optimal dose and efficacy for further development.
2025-06-11 12:05
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Cellectar Biosciences announced the exercise of outstanding warrants to raise $2.5 million, with 8,301,322 shares purchasable at $0.3041 per share. Proceeds will be used for general corporate purposes. The company is a clinical-stage biopharma focused on cancer drug development.
2025-06-05 13:00
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Cellectar Biosciences announced that the FDA granted Breakthrough Therapy Designation for iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM), supported by Phase 2 data showing an 83.6% overall response rate. The company is seeking EMA guidance on submitting a fast-track, conditional marketing authorization application, with a decision expected in late July.
2025-06-04 12:05
